ARTV - Artiva Biotherapeutics, Inc.
About Artiva Biotherapeutics, Inc. (https://www.artivabio.com)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Fred Aslan | CEO, Principal Financial & Accounting Officer and Director | 1975 | $1,215,515 USD |
| Jennifer Kinsbruner Bush | Chief Operating Officer | 1975 | $839,214 USD |
| Christopher Horan | Chief Technical Operations Officer | 1967 | $777,619 USD |
| Peter Flynn | Co-Founder & Strategic Advisor | 1974 | $499,368 USD |
| Gines Diego Miralles | President and Head of Research & Development | 1963 | $55,000 USD |
| Andrew Cronauer | VP, General Counsel & Corporate Secretary | – | – |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs | – | – |
| David Moriarty | Senior Vice President of Clinical Operations | – | – |
| Heather Raymon | Senior Vice President of Research & Early Development | 1965 | – |
| Nicholas Veomett | Vice President of Corporate Development | – | – |